Literature DB >> 3798996

Nitrate therapy without loss of action by correct dosage.

A Boertz, R Bonn.   

Abstract

Previous studies carried out with ISDN prove that long lasting, unfluctuating plasma concentrations--e.g. above 300 ng IS-5-N/ml--cause a severe loss of action. This could be cancelled by administration of isosorbide dinitrate (ISDN) according to a regimen in which an interval with considerably reduced nitrate levels is guaranteed. On the other hand a dosage regimen which leads to steady state plasma concentrations which fluctuate between 100 and 300 ng IS-5-N/ml (after 3 times daily 20 mg ISDN) showed no clinically significant loss of efficacy even after 4 weeks of application. Based on these findings a therapy like once daily 120 mg ISDN sustained release which guarantees plasma levels of up to 600 ng IS-5-N/ml (over the active day of the patient) with an interval of nitrate levels down to 100 ng (overnight) could be judged as efficient. As recent studies showed there is no clinically found loss of efficacy after four week application. With regard to a better compliance this regimen seemed to be the optimum.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3798996

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  3 in total

1.  Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate.

Authors:  F Wagner; F Siefert; D Trenk; E Jähnchen
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.

Authors:  S Silber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Haemodynamic effects of glyceryl trinitrate following repeated application of a transdermal delivery system with a phasic release profile.

Authors:  A Wiegand; R Bonn; F Wagner; D Trenk; E Jähnchen
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.